Iovance Biotherapeutics(GB:0JDK)
$7.38-0.08 (-1.07%)
GB:0JDK
Iovance Biotherapeutics financials statements
$7.38
At close:-0.08 (-1.07%)
Iovance Biotherapeutics (0JDK) Ratios
5 Followers
Iovance Biotherapeutics Ratios
GB:0JDK's free cash flow for Q3 2026 was $-9.21M. For the 2026 fiscal year, GB:0JDK's free cash flow was decreased by $-4.74M and operating cash flow was $-4.47M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.20 | 3.74 | 2.79 | 5.24 | 5.69 |
| Quick Ratio | 2.83 | 3.31 | 2.70 | 5.24 | 5.69 |
| Cash Ratio | 1.18 | 0.95 | 1.04 | 2.53 | 0.88 |
| Solvency Ratio | -1.60 | -1.64 | -2.10 | -2.28 | -2.11 |
| Operating Cash Flow Ratio | -2.19 | -2.89 | -3.28 | -3.20 | -2.56 |
| Short-Term Operating Cash Flow Coverage | -74.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 228.10M | $ 257.00M | $ 112.11M | $ 314.77M | $ 352.28M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.06 | 0.10 | 0.13 | 0.09 |
| Debt-to-Equity Ratio | 0.07 | 0.08 | 0.13 | 0.17 | 0.12 |
| Debt-to-Capital Ratio | 0.06 | 0.08 | 0.11 | 0.15 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.28 | 1.33 | 1.33 | 1.25 |
| Debt Service Coverage Ratio | -86.28 | 0.00 | 0.00 | -126.55 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -133.63 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.14 | 0.20 | 0.32 | 0.56 | 0.47 |
| Net Debt to EBITDA | 0.33 | 0.17 | 0.09 | 0.39 | 0.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 34.28% | 24.43% | -804.54% | 0.00% | 0.00% |
| EBIT Margin | -151.12% | -228.56% | -38734.99% | 0.00% | 0.00% |
| EBITDA Margin | -133.16% | -201.99% | -35948.86% | 0.00% | 0.00% |
| Operating Profit Margin | -151.12% | -240.92% | -38734.99% | 0.00% | 0.00% |
| Pretax Profit Margin | -149.16% | -228.56% | -37638.02% | 0.00% | 0.00% |
| Net Profit Margin | -148.38% | -226.84% | -37345.42% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -148.38% | -226.84% | -37345.42% | 0.00% | 0.00% |
| Net Income Per EBT | 99.47% | 99.25% | 99.22% | 100.00% | 100.00% |
| EBT Per EBIT | 98.70% | 94.87% | 97.17% | 99.25% | 99.87% |
| Return on Assets (ROA) | -42.82% | -40.88% | -56.90% | -59.62% | -44.03% |
| Return on Equity (ROE) | -55.97% | -52.39% | -75.95% | -79.24% | -55.05% |
| Return on Capital Employed (ROCE) | -51.39% | -50.16% | -68.74% | -69.67% | -49.80% |
| Return on Invested Capital (ROIC) | -50.86% | -48.98% | -67.42% | -68.17% | -49.44% |
| Return on Tangible Assets | -61.68% | -59.26% | -80.57% | -59.62% | -44.03% |
| Earnings Yield | -40.08% | -17.35% | -23.23% | -38.90% | -11.69% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.20 | 2.37 | 7.87 | 0.00 | 0.00 |
| Payables Turnover | 7.82 | 4.51 | 0.32 | 0.00 | 0.00 |
| Inventory Turnover | 3.35 | 2.41 | 1.04 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.49 | 1.00 | 0.01 | 0.00 | 0.00 |
| Asset Turnover | 0.29 | 0.18 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.82 | 0.62 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 176.42 | 224.94 | -725.76 | 0.00 | 0.00 |
| Days of Sales Outstanding | 114.21 | 154.26 | 46.35 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 108.92 | 151.66 | 352.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 46.70 | 80.98 | 1124.12 | 0.00 | 0.00 |
| Operating Cycle | 223.12 | 305.92 | 398.36 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.85 | -1.22 | -1.54 | -1.84 | -1.49 |
| Free Cash Flow Per Share | -0.94 | -1.26 | -1.63 | -1.97 | -1.73 |
| Dividend Paid and CapEx Coverage Ratio | -8.94 | -31.89 | -16.23 | -14.33 | -6.07 |
| Capital Expenditure Coverage Ratio | -8.94 | -31.89 | -16.23 | -14.33 | -6.07 |
| Operating Cash Flow Coverage Ratio | -6.24 | -6.06 | -4.77 | -3.43 | -3.19 |
| Operating Cash Flow to Sales Ratio | -1.15 | -2.15 | -304.31 | 0.00 | 0.00 |
| Free Cash Flow Yield | -34.47% | -16.97% | -20.09% | -30.77% | -9.07% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.50 | -5.78 | -4.31 | -2.57 | -8.56 |
| Price-to-Sales (P/S) Ratio | 3.70 | 13.07 | 1607.75 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.40 | 3.02 | 3.27 | 2.04 | 4.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.90 | -5.89 | -4.98 | -3.25 | -11.03 |
| Price-to-Operating Cash Flow Ratio | -3.23 | -6.08 | -5.28 | -3.48 | -12.85 |
| Price-to-Earnings Growth (PEG) Ratio | 0.17 | 0.18 | 0.18 | -0.22 | -0.46 |
| Enterprise Value Multiple | -2.45 | -6.30 | -4.38 | -2.31 | -8.89 |
| Enterprise Value | 860.92M | 2.09B | 1.87B | 871.38M | 2.92B |
| EV to EBITDA | -2.45 | -6.30 | -4.38 | -2.31 | -8.89 |
| EV to Sales | 3.27 | 12.72 | 1574.93 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.56 | -5.73 | -4.88 | -2.78 | -11.00 |
| EV to Operating Cash Flow | -2.85 | -5.91 | -5.18 | -2.98 | -12.82 |
| Tangible Book Value Per Share | 1.17 | 1.48 | 1.51 | 3.14 | 4.05 |
| Shareholders’ Equity Per Share | 1.95 | 2.45 | 2.49 | 3.14 | 4.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Revenue Per Share | 0.74 | 0.57 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -1.09 | -1.28 | -1.89 | -2.49 | -2.23 |
| Tax Burden | 0.99 | 0.99 | 0.99 | 1.00 | 1.00 |
| Interest Burden | 0.99 | 1.00 | 0.97 | 0.99 | 1.00 |
| Research & Development to Revenue | 1.14 | 1.72 | 289.38 | 0.00 | 0.00 |
| SG&A to Revenue | 0.58 | 0.93 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.23 | 0.67 | 52.67 | 0.00 | 0.00 |
| Income Quality | 0.77 | 0.95 | 0.81 | 0.74 | 0.67 |
Currency in USD

